# The Efficacy and Safety of PD-1/PD-L1 Inhibitors Combined With Centipeda Minima (CM) in Lung Cancer

> **NCT05735028** · PHASE1 · UNKNOWN · sponsor: **Second Affiliated Hospital, School of Medicine, Zhejiang University** · enrollment: 8 (estimated)

## Conditions studied

- Lung Cancer

## Interventions

- **DRUG:** Centipeda minima+PD-1/PD-L1 inhibitor
- **DRUG:** PD-1/PD-L1 inhibitor

## Key facts

- **NCT ID:** NCT05735028
- **Lead sponsor:** Second Affiliated Hospital, School of Medicine, Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2024-02-07
- **Primary completion:** 2025-08-07
- **Final completion:** 2025-12-07
- **Target enrollment:** 8 (ESTIMATED)
- **Last updated:** 2024-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05735028

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05735028, "The Efficacy and Safety of PD-1/PD-L1 Inhibitors Combined With Centipeda Minima (CM) in Lung Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05735028. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*